{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:11:32Z","timestamp":1790820692269,"version":"4.1.0"},"reference-count":92,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>This study aims to investigate adverse drug reaction signals associated with coagulopathies through data mining using the Adverse Event Reporting System (FAERS) of the US Food and Drug Administration. Prompt identification of high-risk drugs provides a valuable basis for enhancing clinical drug safety.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The adverse event reports related to coagulopathies from Q1 2004 to Q2 2024 were extracted from the ASCII data packages in FAERS. The reporting odds ratio (ROR), proportional reporting ratio (PRR), and Bayesian confidence propagation neural network (BCPNN) were used to identify adverse drug reaction signals associated with coagulopathies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>During the reporting period, 40,545 reports were retrieved, with a slightly higher proportion of females than males. Among the top 30 drugs associated with the occurrence of coagulopathies, 24 drugs exhibited positive signals in risk analysis. Based on the individual drug reporting odds ratio (95% confidence interval) as a measure of risk signal strength, the top five drugs are as follows: gemcitabine [ROR (95% CI):16.87 (15.83\u201317.98)], busulfan [ROR (95% CI):15.51 (13.69\u201317.58)], anti-thymocyte globulin [ROR (95% CI):15.49 (13.49\u201317.78)], tacrolimus [ROR (95% CI):12.7 (11.57\u201313.95)], etonogestrel and ethinylestradiol vaginal ring [ROR (95% CI):11.88 (10.95\u201312.89)]. After categorizing the drugs, the strongest risk signal is sex hormones and modulators of the genital system [ROR (95% CI):11.88 (10.95\u201312.89)], followed by analgesics [ROR (95%CI): 6.73 (6.38\u20137.1)], immunosuppressants [ROR (95% CI):3.91 (3.76\u20134.05)], antineoplastic agents [ROR (95% CI):3.33 (3.22\u20133.45)], corticosteroids for systemic use [ROR (95% CI): 2.94 (2.73\u20133.18)], antiepileptics [ROR (95% CI):1.93 (1.71\u20132.18)], drugs used in diabetes [ROR (95% CI):1.5 (1.34\u20131.67)], antibacterials for systemic use [ROR (95% CI):1.46 (1.28\u20131.68)].<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our findings indicate that multiple drugs are associated with an increased risk of coagulopathies. From the pharmacovigilance perspective, proactive analysis of these drugs aids in clinical monitoring and enhances risk identification of coagulopathies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1486422","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T06:45:37Z","timestamp":1734504337000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Drug-induced coagulopathies: a real-world pharmacovigilance study using the FDA adverse event reporting system"],"prefix":"10.3389","volume":"15","author":[{"given":"Yanjun","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shita","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.34067\/kid.0000000000000061","article-title":"Chemotherapy-associated thrombotic microangiopathy","volume":"4","author":"Aklilu","year":"2023","journal-title":"Kidney360"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1364110","DOI":"10.3389\/fphar.2024.1364110","article-title":"Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database","volume":"15","author":"Alenzi","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","article-title":"Drug-induced thrombotic microangiopathy: a systematic review of published reports","volume":"125","author":"Al-Nouri","year":"2015","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","article-title":"VEGF in signaling and disease: beyond discovery and development","volume":"176","author":"Apte","year":"2019","journal-title":"Cell"},{"key":"B5","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/jth.15195","article-title":"Managing the coagulopathy associated with cardiopulmonary bypass","volume":"19","author":"Bartoszko","year":"2021","journal-title":"J. Thrombosis Haemostasis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"102322","DOI":"10.1016\/j.ctrv.2021.102322","article-title":"Interplay between coagulation and inflammation in cancer: limitations and therapeutic opportunities","volume":"102","author":"Bauer","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"B7","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.survophthal.2016.03.003","article-title":"Acute macular neuroretinopathy: a comprehensive review of the literature","volume":"61","author":"Bhavsar","year":"2016","journal-title":"Surv. Ophthalmol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jvs.2005.04.027","article-title":"Clopidogrel has no effect on D-dimer and thrombin-antithrombin III levels in patients with peripheral arterial disease undergoing peripheral percutaneous transluminal angioplasty","volume":"42","author":"Cassar","year":"2005","journal-title":"J. Vasc. Surg."},{"key":"B9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.emc.2013.10.001","article-title":"Toxin-induced coagulopathy","volume":"32","author":"Chai","year":"2014","journal-title":"Emerg. Med. Clin. N. Am."},{"key":"B10","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s00467-014-3036-8","article-title":"De novo tacrolimus-induced thrombotic microangiopathy in the early stage after renal transplantation successfully treated with conversion to everolimus","volume":"30","author":"Cortina","year":"2015","journal-title":"Pediatr. Nephrol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1007\/s11096-019-00912-5","article-title":"Tigecycline-induced coagulopathy: a literature review","volume":"41","author":"Cui","year":"2019","journal-title":"Int. J. Clin. Pharm."},{"key":"B12","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1681\/asn.2018080853","article-title":"Therapeutic inhibition of VEGF signaling and associated nephrotoxicities","volume":"30","author":"Estrada","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","article-title":"Non\u2013small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Ettinger","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"B14","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1417596","DOI":"10.3389\/fphar.2024.1417596","article-title":"Risk of drug-induced angioedema: a pharmacovigilance study of FDA adverse event reporting system database","volume":"15","author":"Fan","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"16037","DOI":"10.1038\/nrdp.2016.37","article-title":"Disseminated intravascular coagulation","volume":"2","author":"Gando","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B17","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"297","DOI":"10.22336\/rjo.2019.46","article-title":"Assessing the effectiveness of OTC Advertising on artificial tear drops from an experiential marketing perspective","volume":"63","author":"Gheorghe","year":"2019","journal-title":"romanian J. Ophthalmol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1177\/1076029616683802","article-title":"Oral contraceptives and HRT risk of thrombosis","volume":"24","author":"Gialeraki","year":"2017","journal-title":"Clin. Appl. Thrombosis\/Hemostasis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e25874","DOI":"10.7759\/cureus.25874","article-title":"Tacrolimus-induced thrombotic microangiopathy after orthotopic heart transplant: a case report","volume":"14","author":"Gill","year":"2022","journal-title":"Cureus"},{"key":"B21","doi-asserted-by":"publisher","first-page":"100864","DOI":"10.1016\/j.blre.2021.100864","article-title":"Coagulopathy and sepsis: pathophysiology, clinical manifestations and treatment","volume":"50","author":"Giustozzi","year":"2021","journal-title":"Blood Rev."},{"key":"B22","doi-asserted-by":"publisher","first-page":"100742","DOI":"10.1016\/j.cpcardiol.2020.100742","article-title":"Thrombosis and coagulopathy in COVID-19","volume":"46","author":"G\u00f3mez-Mesa","year":"2021","journal-title":"Curr. Problems Cardiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s12882-021-02470-3","article-title":"Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre","volume":"22","author":"Grall","year":"2021","journal-title":"BMC Nephrol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12959-022-00369-z","article-title":"Coagulation dysfunction events associated with tigecycline: a real-world study from FDA adverse event reporting system (FAERS) database","volume":"20","author":"Guo","year":"2022","journal-title":"Thrombosis J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/liv.12369","article-title":"Evidence of rebalanced coagulation in acute liver injury and acute liver failure as measured by thrombin generation","volume":"34","author":"Habib","year":"2013","journal-title":"Liver Int."},{"key":"B26","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1080\/1120009x.2018.1452333","article-title":"Impact of tigecycline versus imipenem\u2013cilastatin on fibrinogen levels following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): a randomized-controlled study","volume":"30","author":"Hakeam","year":"2018","journal-title":"J. Chemother."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/aogs.14428","article-title":"Combined oral contraceptives containing estradiol valerate vs ethinylestradiol on coagulation: a randomized clinical trial","volume":"101","author":"Haverinen","year":"2022","journal-title":"Acta Obstetricia Gynecol. Scand."},{"key":"B28","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00134-023-06980-6","article-title":"How to manage coagulopathies in critically ill patients","volume":"49","author":"Helms","year":"2023","journal-title":"Intensive Care Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s12032-013-0568-x","article-title":"Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report","volume":"30","author":"Iams","year":"2013","journal-title":"Med. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1097\/aln.0000000000003122","article-title":"Sepsis-induced coagulopathy and disseminated intravascular coagulation","volume":"132","author":"Iba","year":"2020","journal-title":"Anesthesiology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.thromres.2019.04.030","article-title":"The progression from coagulopathy to disseminated intravascular coagulation in representative underlying diseases","volume":"179","author":"Iba","year":"","journal-title":"Thrombosis Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1111\/jth.14578","article-title":"Diagnosis and management of sepsis\u2010induced coagulopathy and disseminated intravascular coagulation","volume":"17","author":"Iba","year":"","journal-title":"J. Thrombosis Haemostasis"},{"key":"B33","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12905-021-01302-8","article-title":"Neutropenic enterocolitis-induced sepsis and disseminated intravascular coagulation after chemotherapy: a case report","volume":"21","author":"Ishikawa","year":"2021","journal-title":"BMC Women's Health"},{"key":"B34","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1053\/j.ajkd.2015.02.340","article-title":"Thrombotic microangiopathy, cancer, and cancer drugs","volume":"66","author":"Izzedine","year":"2015","journal-title":"Am. J. Kidney Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1080\/14740338.2023.2189698","article-title":"Adverse effects of proton pump inhibitors (PPIs) on the renal system using data mining algorithms (DMAs)","volume":"22","author":"Jain","year":"2023","journal-title":"Expert Opin. Drug Saf."},{"key":"B36","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2174\/1574886318666230228142856","article-title":"Identification of signal of clindamycin associated renal failure acute: a disproportionality analysis","volume":"19","author":"Javed","year":"2024","journal-title":"Curr. Drug Saf."},{"key":"B37","doi-asserted-by":"publisher","first-page":"20420986231224227","DOI":"10.1177\/20420986231224227","article-title":"Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System from 2004 to 2021","volume":"15","author":"Jiang","year":"2024","journal-title":"Ther. Adv. Drug Saf."},{"key":"B38","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.blre.2014.11.001","article-title":"A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury","volume":"29","author":"Jodele","year":"2015","journal-title":"Blood Rev."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1007\/s00134-022-06834-7","article-title":"Trauma-induced coagulopathy","volume":"48","author":"Kleinveld","year":"2022","journal-title":"Intensive Care Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/pds.964","article-title":"Comparison of data mining methodologies using Japanese spontaneous reports","volume":"13","author":"Kubota","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B41","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.pediatrneurol.2019.04.019","article-title":"Valproic acid\u2013induced coagulopathy","volume":"98","author":"Kumar","year":"2019","journal-title":"Pediatr. Neurol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1002\/hep.20948","article-title":"Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study","volume":"42","author":"Larson","year":"2005","journal-title":"Hepatology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/MD.0b013e3182603598","article-title":"Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases","volume":"91","author":"Lechner","year":"2012","journal-title":"Medicine"},{"key":"B44","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1016\/s0049-3848(14)50012-6","article-title":"Cancer-related coagulopathies","volume":"133","author":"Levi","year":"2014","journal-title":"Thrombosis Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/cpt.3139","article-title":"Drug\u2010induced acute pancreatitis: a real\u2010world pharmacovigilance study using the FDA adverse event reporting system database","volume":"115","author":"Li","year":"2024","journal-title":"Clin. Pharmacol. and Ther."},{"key":"B46","doi-asserted-by":"publisher","first-page":"10760296231195089","DOI":"10.1177\/10760296231195089","article-title":"Potential biomarkers for early diagnosis, evaluation, and prognosis of sepsis-induced coagulopathy","volume":"29","author":"Li","year":"2023","journal-title":"Clin. Appl. Thrombosis\/Hemostasis"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1290975","DOI":"10.3389\/fphar.2024.1290975","article-title":"A real-world disproportionality analysis of mesalazine data mining of the public version of FDA adverse event reporting system","volume":"15","author":"Liu","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1055\/s-0036-1593417","article-title":"Management of coagulopathy in postpartum hemorrhage","volume":"42","author":"Lockhart","year":"2016","journal-title":"Seminars Thrombosis Hemostasis"},{"key":"B49","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/09273948.2021.1998549","article-title":"Tacrolimus induced thrombotic microangiopathy (TMA) presenting as acute macular neuroretinopathy","volume":"31","author":"Markan","year":"2021","journal-title":"Ocular Immunol. Inflamm."},{"key":"B50","doi-asserted-by":"publisher","first-page":"v7","DOI":"10.1093\/annonc\/mdj941","article-title":"Cellular pharmacology of gemcitabine","volume":"17","author":"Mini","year":"2006","journal-title":"Ann. Oncol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/jth.14690","article-title":"Defining trauma\u2010induced coagulopathy with respect to future implications for patient management: communication from the SSC of the ISTH","volume":"18","author":"Moore","year":"2020","journal-title":"J. Thrombosis Haemostasis"},{"key":"B52","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40780-018-0109-z","article-title":"Signals of gastroesophageal reflux disease caused by incretin-based drugs: a disproportionality analysis using the Japanese adverse drug event report database","volume":"4","author":"Noguchi","year":"2018","journal-title":"J. Pharm. Health Care Sci."},{"key":"B53","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.3109\/10428194.2012.682313","article-title":"Rituximab-induced coagulopathy","volume":"53","author":"Novak","year":"2012","journal-title":"Leukemia and Lymphoma"},{"key":"B54","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/imj.12048","article-title":"Tacrolimus\u2010induced thrombotic microangiopathy in orthotopic liver transplant patients: case series of four patients","volume":"43","author":"Nwaba","year":"2013","journal-title":"Intern. Med. J."},{"key":"B55","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3390\/genes13030466","article-title":"Recent development of prodrugs of gemcitabine","volume":"13","author":"Pandit","year":"2022","journal-title":"Genes"},{"key":"B56","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1097\/mcc.0000000000000676","article-title":"Coagulopathy in the surgical patient: trauma-induced and drug-induced coagulopathies","volume":"25","author":"Peralta","year":"2019","journal-title":"Curr. Opin. Crit. Care"},{"key":"B57","doi-asserted-by":"publisher","first-page":"020","DOI":"10.1055\/s-0039-1677853","article-title":"Trauma-induced coagulopathy","volume":"39","author":"Petros","year":"2019","journal-title":"H\u00e4mostaseologie"},{"key":"B58","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1053\/ajkd.2000.17690","article-title":"Cyclosporine and tacrolimus\u2013associated thrombotic microangiopathy","volume":"36","author":"Pham","year":"2000","journal-title":"Am. J. Kidney Dis."},{"key":"B59","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/pds.1746","article-title":"Drug\u2010induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS)","volume":"18","author":"Poluzzi","year":"2009","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B60","doi-asserted-by":"publisher","first-page":"5346","DOI":"10.1038\/s41467-023-40852-3","article-title":"Low-dose carboplatin modifies the tumor microenvironment to augment CAR T cell efficacy in human prostate cancer models","volume":"14","author":"Porter","year":"2023","journal-title":"Nat. Commun."},{"key":"B61","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11523-020-00738-6","article-title":"Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: a clinical perspective from pharmacovigilance","volume":"15","author":"Raschi","year":"","journal-title":"Target. Oncol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/bjd.19677","article-title":"The value of case reports and spontaneous reporting systems for pharmacovigilance and clinical practice","volume":"184","author":"Raschi","year":"","journal-title":"Br. J. Dermatology"},{"key":"B63","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s11523-019-00632-w","article-title":"Toxicities with immune checkpoint inhibitors: emerging priorities from disproportionality analysis of the FDA adverse event reporting system","volume":"14","author":"Raschi","year":"2019","journal-title":"Target. Oncol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B65","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ijantimicag.2014.07.014","article-title":"High-dose tigecycline-associated alterations in coagulation parameters in critically ill patients with severe infections","volume":"45","author":"Routsi","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B66","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1093\/ckj\/sfaa101","article-title":"Complement C5 inhibition reverses bleomycin-induced thrombotic microangiopathy","volume":"14","author":"Salhi","year":"2021","journal-title":"Clin. Kidney J."},{"key":"B68","doi-asserted-by":"publisher","first-page":"5530","DOI":"10.3390\/ijerph18115530","article-title":"Consumption of over-the-Counter drugs: prevalence and type of drugs","volume":"18","author":"S\u00e1nchez-S\u00e1nchez","year":"2021","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B69","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/ane.13690","article-title":"Identification of novel signal of clobazam\u2010associated drug reaction with eosinophilia and systemic symptoms syndrome: a disproportionality analysis","volume":"146","author":"Sharma","year":"2022","journal-title":"Acta Neurol. Scand."},{"key":"B70","doi-asserted-by":"publisher","first-page":"e28671","DOI":"10.1002\/jmv.28671","article-title":"Association of antiviral drugs and their possible mechanisms with DRESS syndrome using data mining algorithms","volume":"95","author":"Sharma","year":"2023","journal-title":"J. Med. Virology"},{"key":"B71","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40779-020-00247-7","article-title":"Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19","volume":"7","author":"Song","year":"2020","journal-title":"Mil. Med. Res."},{"key":"B72","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/mcc.0000000000000466","article-title":"Early haemorrhage control and management of trauma-induced coagulopathy: the importance of goal-directed therapy","volume":"23","author":"Stensballe","year":"2017","journal-title":"Curr. Opin. Crit. Care"},{"key":"B73","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ajp.2017.09.005","article-title":"Novel adverse events of vortioxetine: a disproportionality analysis in USFDA adverse event reporting system database","volume":"30","author":"Subeesh","year":"2017","journal-title":"Asian J. Psychiatry"},{"key":"B74","doi-asserted-by":"publisher","first-page":"e2022398","DOI":"10.1001\/jamanetworkopen.2020.22398","article-title":"Comparison of acetaminophen (paracetamol) with ibuprofen for treatment of fever or pain in children younger than 2 Years: a systematic review and meta-analysis","volume":"3","author":"Tan","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"B75","doi-asserted-by":"publisher","first-page":"970066","DOI":"10.3389\/fphar.2022.970066","article-title":"Adverse reaction signals mining and hemorrhagic signals comparison of ticagrelor and clopidogrel: a pharmacovigilance study based on FAERS","volume":"13","author":"Tang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1001\/jama.2021.21392","article-title":"Contraception selection, effectiveness, and adverse effects: a review","volume":"326","author":"Teal","year":"2021","journal-title":"Jama"},{"key":"B77","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00228-010-0790-9","article-title":"A pilot study to evaluate a community pharmacy\u2013based monitoring system to identify adverse drug reactions associated with paediatric medicines use","volume":"66","author":"Tobaiqy","year":"2010","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"4702","DOI":"10.3390\/jcm10204702","article-title":"Progression of fibrinogen decrease during high dose tigecycline therapy in critically ill patients: a retrospective analysis","volume":"10","author":"Treml","year":"2021","journal-title":"J. Clin. Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine\u2013cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B80","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1053\/j.seminhematol.2007.01.004","article-title":"Sex hormones and thrombosis","volume":"44","author":"Watson","year":"2007","journal-title":"Seminars Hematol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"i2002","DOI":"10.1136\/bmj.i2002","article-title":"Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study","volume":"353","author":"Weill","year":"2016","journal-title":"Bmj"},{"key":"B82","doi-asserted-by":"publisher","first-page":"e335","DOI":"10.1016\/j.clinthera.2021.10.005","article-title":"A comparison of coagulation function in patients receiving aspirin and cefoperazone-sulbactam with and without vitamin K1: a retrospective, observational study","volume":"43","author":"Wu","year":"2021","journal-title":"Clin. Ther."},{"key":"B83","doi-asserted-by":"publisher","first-page":"e71193","DOI":"10.1371\/journal.pone.0071193","article-title":"The GPVI \u2013 Fc fusion protein revacept reduces thrombus formation and improves vascular dysfunction in atherosclerosis without any impact on bleeding times","volume":"8","author":"Xiao","year":"2013","journal-title":"PLoS ONE"},{"key":"B84","doi-asserted-by":"publisher","first-page":"925377","DOI":"10.3389\/fphar.2022.925377","article-title":"GLP-1 receptor agonist-associated tumor adverse events: a real-world study from 2004 to 2021 based on FAERS","volume":"13","author":"Yang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/pde.14091","article-title":"The influence of social media on acne treatment: a cross\u2010sectional survey","volume":"37","author":"Yousaf","year":"2020","journal-title":"Pediatr. Dermatol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1231320","DOI":"10.3389\/fphar.2023.1231320","article-title":"Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS)","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1407709","DOI":"10.3389\/fphar.2024.1407709","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for sunitinib","volume":"15","author":"Zhang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"637434","DOI":"10.3389\/fmed.2020.637434","article-title":"A machine-learning approach for dynamic prediction of sepsis-induced coagulopathy in critically ill patients with sepsis","volume":"7","author":"Zhao","year":"2021","journal-title":"Front. Med."},{"key":"B90","doi-asserted-by":"publisher","first-page":"103828","DOI":"10.1016\/j.ajp.2023.103828","article-title":"Adverse events of epidiolex: a real-world drug safety surveillance study based on the FDA adverse event reporting system (FAERS) database","volume":"90","author":"Zhou","year":"2023","journal-title":"Asian J. Psychiatry"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1320458","DOI":"10.3389\/fphar.2023.1320458","article-title":"A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database","volume":"14","author":"Zou","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/s1470-2045(07)70203-6","article-title":"Gemcitabine-associated thrombotic thrombocytopenic purpura","volume":"8","author":"Zupancic","year":"2007","journal-title":"Lancet Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1486422\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T06:45:43Z","timestamp":1734504343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1486422\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":92,"alternative-id":["10.3389\/fphar.2024.1486422"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1486422","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"article-number":"1486422"}}